Nivolumab, a PD-1 blocking antibody, caused the highest frequency of TB reactivation, while avelumab, which is one of the blocking antibodies of PD-L1, did not cause any events of TB or atypical infections (3). The gene discussed is CD274; the disease is tuberculosis.